-+ 0.00%
-+ 0.00%
-+ 0.00%

BeiGene announced that in the first half of 2026, the company's total revenue was 22.220 billion yuan, up 26.8% year on year; net profit attributable to parent company owners was 3.271 billion yuan, up 627.1% year on year. The increase in product revenue was mainly due to sales growth of products authorized by Baiyue Ze, Amgen, and Baizean. In addition, the company announced an additional investment of 300 million US dollars to expand its R&D center in the US and appointed three new board members.

Zhitongcaijing·08/05/2026 10:33:44
Listen to the news
BeiGene announced that in the first half of 2026, the company's total revenue was 22.220 billion yuan, up 26.8% year on year; net profit attributable to parent company owners was 3.271 billion yuan, up 627.1% year on year. The increase in product revenue was mainly due to sales growth of products authorized by Baiyue Ze, Amgen, and Baizean. In addition, the company announced an additional investment of 300 million US dollars to expand its R&D center in the US and appointed three new board members.